Cardiovascular effects in childhood cancer survivors treated with anthracyclines

Steven E Lipshultz, Vivian I. Franco, Jacqueline M. Henkel, Tracie L Miller

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to a growing population of long-term childhood cancer survivors. However, their use is limited by cardiotoxicity, increasing survivors' vulnerability to treatment-related complications that can markedly affect their quality of life. Survivors are more likely to suffer from heart failure, coronary artery disease, and cerebrovascular accidents compared to the general population. The specific mechanisms of anthracycline cardiotoxicity are complex and remain unclear. Hence, determining the factors that may increase susceptibility to cardiotoxicity is of great importance, as is monitoring patients during and after treatment. Additionally, treatment and prevention options, such as limiting cumulative dosage, liposomal anthracyclines, and dexrazoxane, continue to be explored. Here, we review the cardiovascular complications associated with the use of anthracyclines in treating malignancies in children and discuss methods for preventing, screening, and treating such complications in childhood cancer survivors.

Original languageEnglish
Article number134679
JournalCardiology Research and Practice
Volume1
Issue number1
DOIs
StatePublished - Jun 27 2011

Fingerprint

Anthracyclines
Survivors
Neoplasms
Dexrazoxane
Physiologic Monitoring
Population
Coronary Artery Disease
Lymphoma
Leukemia
Therapeutics
Heart Failure
Stroke
Quality of Life
Cardiotoxicity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiovascular effects in childhood cancer survivors treated with anthracyclines. / Lipshultz, Steven E; Franco, Vivian I.; Henkel, Jacqueline M.; Miller, Tracie L.

In: Cardiology Research and Practice, Vol. 1, No. 1, 134679, 27.06.2011.

Research output: Contribution to journalArticle

Lipshultz, Steven E ; Franco, Vivian I. ; Henkel, Jacqueline M. ; Miller, Tracie L. / Cardiovascular effects in childhood cancer survivors treated with anthracyclines. In: Cardiology Research and Practice. 2011 ; Vol. 1, No. 1.
@article{992cfa78b5904754901aa88e21a5c012,
title = "Cardiovascular effects in childhood cancer survivors treated with anthracyclines",
abstract = "Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to a growing population of long-term childhood cancer survivors. However, their use is limited by cardiotoxicity, increasing survivors' vulnerability to treatment-related complications that can markedly affect their quality of life. Survivors are more likely to suffer from heart failure, coronary artery disease, and cerebrovascular accidents compared to the general population. The specific mechanisms of anthracycline cardiotoxicity are complex and remain unclear. Hence, determining the factors that may increase susceptibility to cardiotoxicity is of great importance, as is monitoring patients during and after treatment. Additionally, treatment and prevention options, such as limiting cumulative dosage, liposomal anthracyclines, and dexrazoxane, continue to be explored. Here, we review the cardiovascular complications associated with the use of anthracyclines in treating malignancies in children and discuss methods for preventing, screening, and treating such complications in childhood cancer survivors.",
author = "Lipshultz, {Steven E} and Franco, {Vivian I.} and Henkel, {Jacqueline M.} and Miller, {Tracie L}",
year = "2011",
month = "6",
day = "27",
doi = "10.4061/2011/134679",
language = "English",
volume = "1",
journal = "Cardiology Research and Practice",
issn = "2090-8016",
publisher = "Hindawi Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - Cardiovascular effects in childhood cancer survivors treated with anthracyclines

AU - Lipshultz, Steven E

AU - Franco, Vivian I.

AU - Henkel, Jacqueline M.

AU - Miller, Tracie L

PY - 2011/6/27

Y1 - 2011/6/27

N2 - Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to a growing population of long-term childhood cancer survivors. However, their use is limited by cardiotoxicity, increasing survivors' vulnerability to treatment-related complications that can markedly affect their quality of life. Survivors are more likely to suffer from heart failure, coronary artery disease, and cerebrovascular accidents compared to the general population. The specific mechanisms of anthracycline cardiotoxicity are complex and remain unclear. Hence, determining the factors that may increase susceptibility to cardiotoxicity is of great importance, as is monitoring patients during and after treatment. Additionally, treatment and prevention options, such as limiting cumulative dosage, liposomal anthracyclines, and dexrazoxane, continue to be explored. Here, we review the cardiovascular complications associated with the use of anthracyclines in treating malignancies in children and discuss methods for preventing, screening, and treating such complications in childhood cancer survivors.

AB - Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to a growing population of long-term childhood cancer survivors. However, their use is limited by cardiotoxicity, increasing survivors' vulnerability to treatment-related complications that can markedly affect their quality of life. Survivors are more likely to suffer from heart failure, coronary artery disease, and cerebrovascular accidents compared to the general population. The specific mechanisms of anthracycline cardiotoxicity are complex and remain unclear. Hence, determining the factors that may increase susceptibility to cardiotoxicity is of great importance, as is monitoring patients during and after treatment. Additionally, treatment and prevention options, such as limiting cumulative dosage, liposomal anthracyclines, and dexrazoxane, continue to be explored. Here, we review the cardiovascular complications associated with the use of anthracyclines in treating malignancies in children and discuss methods for preventing, screening, and treating such complications in childhood cancer survivors.

UR - http://www.scopus.com/inward/record.url?scp=79959393878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959393878&partnerID=8YFLogxK

U2 - 10.4061/2011/134679

DO - 10.4061/2011/134679

M3 - Article

C2 - 21331374

AN - SCOPUS:79959393878

VL - 1

JO - Cardiology Research and Practice

JF - Cardiology Research and Practice

SN - 2090-8016

IS - 1

M1 - 134679

ER -